| CROSS COUNTRY INC. | |||
| Boca Raton, Fla. | |||
| Went public 10/25/01 at $17 per share | |||
| Filing Range: | 7.8 million shares at $15 to $17 | ||
| Offering Size: | $125.0 million | ||
| Post Offering Valuation: | $527.3 million | ||
| Shares Outstanding: | 31.02 million shares | ||
| Underwriters: | Merrill Lynch/Salomon Smith Barney/Banc of America Securities/Robinson-Humphrey Co./CIBC World Markets Inc. | ||
| Company Counsel: | Proskauer Rose LLP | ||
| Manager Counsel: | Debevoise & Plimpton | ||
| Auditor: | Ernst & Young LLP | ||
| The Company | |||
| Provides medical staffing and organization services. | |||
| Venture Backers | |||
| Charterhouse Group International Inc. | |||
| Morgan Stanley Venture Partners | |||
| Financing Rounds | |||
| Round # | Round Date | Number of Stage Investors | Round Amt. ($ thousands) |
| 1 | 02/16/2001 | 2 Early Stage | 746.0 |
| Financials | |||
| ($ in million, except EPS) | Y/E 12/31/00 | ||
| Total Revenues: | $367.7 | ||
| Net Income: | 4.6 | ||
| EPS: | 0.29 | ||
| GIVEN IMAGING LTD. | |||
| Yoqneam, Israel | |||
| Went public 10/04/01 at $12 per share | |||
| Filing Range: | 5.0 million shares at $12 to $14 | ||
| Offering Size: | $65.0 million | ||
| Post Offering Valuation: | $300.8 million | ||
| Shares Outstanding: | 25.1 million shares | ||
| Underwriters: | Lehman Brothers/Credit Suisse First Boston/ Robertson Stephens & Co./Fidelity Capital Markets | ||
| Company Counsel: | White & Case LLP | ||
| Manager Counsel: | Bingham Dana LLP | ||
| Auditor: | KPMG International | ||
| The Company | |||
| Develops wireless imaging systems that provide visual examinations of the gastrointestinal tract. The company’s system uses a miniaturized video camera contained in a capsule that is ingested by the patient and delivers color images in a painless and noninvasive manner. | |||
| Venture Backers | |||
| OrbiMed Advisors LLC | |||
| Financing Rounds | |||
| Round # | Round Date | Number of Stage Investors | Round Amt. ($ thousands) |
| 1 | 10/01/2000 | 1 Early Stage | 30,000.0 |
| Financials | |||
| ($ in million, except EPS) | Y/E 12/31/00 | ||
| Total Revenues: | $0.0 | ||
| Net Income: | (7.5) | ||
| EPS: | (0.68) | ||
| LOGICVISION INC. | |||
| San Jose, Calif. | |||
| Went public 10/31/01 at $9 per share | |||
| Filing Range: | 4.5 million shares at $9 to $11 | ||
| Offering Size: | $49.5 million shares | ||
| Post Offering Valuation: | $127.1 million | ||
| Shares Outstanding: | 14.12 million shares | ||
| Underwriters: | UBS Warburg/SG Cowen Securities Corp./Dain Rauscher Wessels | ||
| Company Counsel: | Pillsbury Winthrop LLP | ||
| Manager Counsel: | Gray Cary Ware & Freidenrich | ||
| Auditor: | Pricewaterhouse Coopers LLP | ||
| The Company | |||
| Supplies embedded test solutions to the electronics industry worldwide. LogicVisions product line provides the most complete and cost effective test solution for companies designing and manufacturing highly complex systems. | |||
| Venture Backers | |||
| Citicorp Venture Capital Ltd. | |||
| US Trust Private Equity | |||
| Needham & Company Inc. | |||
| Financing Rounds | |||
| Round # | Round Date | Number of Stage Investors | Round Amt. ($ thousands) |
| 1 | 05/14/1997 | 1 Expansion | 1,249.0 |
| 2 | 03/01/1999 | 1 Expansion | 5,150.0 |
| 3 | 06/01/1999 | 1 Expansion | 3,295.0 |
| 4 | 01/28/2000 | 5 Later Stage | 15,000.0 |
| Financials | |||
| ($ in million, except EPS) | Y/E 12/31/00 | ||
| Total Revenues: | $9.3 | ||
| Net Income: | (12.7) | ||
| EPS: | (1.38) | ||
| ODYSSEY HEALTHCARE INC. | |||
| Dallas, Texas | |||
| Went public 10/31/01 at $15 per share | |||
| Filing Range: | 3.6 million shares at $13 to $15 | ||
| Offering Size: | $50.4 million | ||
| Post Offering Valuation: | $205.7 million | ||
| Shares Outstanding: | 13.7 million shares | ||
| Underwriters: | Merrill Lynch/CIBC World Markets Inc./SG Cowen Securities Corp. | ||
| Company Counsel: | Vinson & Elkins LLP | ||
| Manager Counsel: | Debevoise & Plimpton | ||
| Auditor: | Ernst & Young LLP | ||
| The Company | |||
| Operates more than 30 hospice facilities in about 20 states. The company offers a full range of services, including nursing care, personal care, counseling, and daily living assistance. | |||
| Venture Backers | |||
| Three Arch Partners | |||
| Weiss Peck & Greer | |||
| Oak Investment Partners | |||
| Financing Rounds | |||
| Round # | Round Date | Number of Stage Investors | Round Amt. ($ thousands) |
| 1 | 09/25/1995 | 1 Expansion | 265.0 |
| Financials | |||
| ($ in million, except EPS) | Y/E 12/31/00 | ||
| Total Revenues: | $85.3 | ||
| Net Income: | 3.1 | ||
| EPS: | (0.92) | ||
| THERASENSE INC. | |||
| Alameda, Calif. | |||
| Went public 10/12/01 at $19 per share | |||
| Filing Range: | 6.0 million shares at $18 to $20 | ||
| Offering Size: | $114.0 million | ||
| Post Offering Valuation: | $723.7 million | ||
| Shares Outstanding: | 38.08 million shares | ||
| Underwriters: | US Bancorp Piper Jaffray/SG Cowen Securities/ Thomas Weisel Partners LLC | ||
| Company Counsel: | Wilson Sonsini Goodrich & Rosati | ||
| Manager Counsel: | Brobeck Phleger & Harrison LLP | ||
| Auditor: | Pricewaterhouse Coopers LLP | ||
| The Company | |||
| Manufactures minimally invasive glucose monitoring equipment for diabetics. The company offers a product made to use only 300 nanoliters of blood compared with 2.5 microliters needed by traditional monitoring products to obtain an accurate reading. The company also manufactures a wireless unit made to continuously monitor glucose by using a miniaturized subcutaneous sensor. | |||
| Venture Backers | |||
| InterWest Partners | |||
| Brentwood Venture Capital | |||
| Sequoia Capital | |||
| Delphi Ventures | |||
| Crown Advisors International Ltd. | |||
| Lehman Brothers | |||
| MedVenture Associates | |||
| Financing Rounds | |||
| Round # | Round Date | Number of Stage Investors | Round Amt. ($ thousands) |
| 1 | 04/01/1997 | 3 Early Stage | 55,74.9 |
| 2 | 10/22/1998 | 6 Expansion | 11,882.0 |
| 3 | 02/02/2000 | 2 Expansion | 42,500.0 |
| 4 | 01/23/2001 | 9 Expansion | 55,999.7 |
| Financials | |||
| ($ in million, except EPS) | Y/E 12/31/00 | ||
| Total Revenues: | $5.5 | ||
| Net Income: | (43.6) | ||
| EPS: | (2.06) | ||
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: